Glucocorticoid receptor polymorphismBclI with increased glucocorticoid sensitivity has a positive influence on quality of life in endogenous Cushing's syndrome in remission
Authors' conclusion
BclI minor allele carriers initially had the lowest QoL but recovered better from impaired QoL than wildtype carriers.
Study context
- Population
- Patients with endogenous Cushing's syndrome (CS) (81 active, 214 in remission) from 3 centers of the German Cushing's Registry120 longitudinal
- Participants
- 295 patients
- Exposure
- Glucocorticoid receptor (GR) polymorphism minor allele carriers vs wildtype carriers
- Outcome
- QoL (CushingQoL, Tuebingen CD-25, SF-36) by GR genotype
Methodological detailsmulticentre, German Cushing's Registry
- Multicentre
- German Cushing's Registry
Main finding
As reported in the abstract
QoL by GR genotype
- Cross-sectional: no differences in quality of life (QoL) between minor allele and wildtype carriers for all polymorphisms in active or cured CS
- Minor allele vs Wildtype: P = 0.038
- Minor allele vs Wildtype: P = 0.013
Observational data: associations, not effects.
Further findings
QoL in remission vs active CS
- Remission scored significantly better than active CS in CushingQoL and SF-36 physical and social functioning, role-physical, bodily pain, vitality
CushingQoL and Tuebingen CD-25 (longitudinal) · 1.5 ± 0.9 yrs follow-up
- Improved significantly in both wildtype and minor allele carriers
Original publication
Glucocorticoid receptor polymorphismBclI with increased glucocorticoid sensitivity has a positive influence on quality of life in endogenous Cushing's syndrome in remission. Eur J Endocrinol. Published 30 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →